RYTM News and Press, Rhythm Pharmaceuticals Inc. From 11/09/21

BOSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, President and Chief Exe...

Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2021 Earnings Conference Call Nov 02, 2021 08:00 AM ET Company Participants David Connolly - Head of Investor Relations & Corporate Communications David Meeker - Chairman, President & Chief Executive Officer Linda Shapiro - Chief Medical Officer ...

Rhythm Pharmaceuticals (NASDAQ:RYTM): Q3 GAAP EPS of -$0.70 beats by $0.10. Revenue of $1.02M beats by $0.12M. Press Release For further details see: Rhythm Pharmaceuticals EPS beats by $0.10, beats on revenue

-- U.S. and EU regulatory filings submitted for IMCIVREE ® (setmelanotide) for treatment of Bardet-Biedl and Alström syndromes; launch preparations underway -- -- Delivered a total of 22 presentations at three major medical conferences -- -- New presentat...

-- Additional oral presentation details safety and efficacy data from Phase 3 trial of setmelanotide in BBS -- -- Also presenting new hunger data from SRC1 and SH2B1 cohorts in Phase 2 Basket Trial and new data on utilization of URO ® genetic testing program –...

Rhythm Pharmaceuticals (NASDAQ:RYTM) is scheduled to announce Q3 earnings results on Tuesday, November 2nd, before market open. The consensus EPS Estimate is -$0.80 (-3.9% Y/Y) and the consensus Revenue Estimate is $0.9M. Over the last 3 months, EPS estimates have seen 1 upward revision and 3...

OTCQX:ACDVF,AHH,AME,APO,OTCQX:ARBKF,ARCB,ARNC,AROC,AVNS,BCC,BHC,BLD,BLMN,BP,CEIX,CEN,CMI,COP,CRSR,CTLT,DD,DEA,EL,EOLS,EPD,ESPR,ETN,ETRN,EXTR,FMS,OTCPK:FSNUF,GLDD,GLYC,GNRC,GPN,HEP,HSIC,IAA,IART,IDXX,IEP,INCY,INGR,IPGP,IT,KKR,KOPN,LCII,LDOS,LEA,LGIH,LPX,MGY,MIME,MLM,MMP,MPC,MPLX,MYGN,OTCQB:NLS...

BOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that it will host a live conference call and webcast...

BOSTON, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that it has submitted its Type II variation applicat...

-- New data in patients with POMC or LEPR deficiency obesity show setmelanotide led to clinically meaningful improvements in health related quality of life measures and hunger -- -- Updated results from Uncovering Rare Obesity ® testing program suggest up to 64.5 pe...